Related references
Note: Only part of the references are listed.Causal assessment of smoking and tooth loss: A systematic review of observational studies
Takashi Hanioka et al.
BMC PUBLIC HEALTH (2011)
Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review
Roland Gerull et al.
CRITICAL CARE MEDICINE (2011)
Drug hypersensitivity: Pharmacogenetics and clinical syndromes
Elizabeth J. Phillips et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans
Hye-Ryun Kang et al.
PHARMACOGENETICS AND GENOMICS (2011)
HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients
Nahoko Kaniwa et al.
EPILEPSIA (2010)
HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
Hiroko Ikeda et al.
EPILEPSIA (2010)
Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis
Hayfaa A. Wahabi et al.
BMC PREGNANCY AND CHILDBIRTH (2010)
The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies
Lesley A. Smith et al.
BMC PUBLIC HEALTH (2009)
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
Wichittra Tassaneeyakul et al.
PHARMACOGENETICS AND GENOMICS (2009)
Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study
Maja Mockenhaupt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
Sitna Halevy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis
Nahoko Kaniwa et al.
PHARMACOGENOMICS (2008)
Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics
Yasong Lu et al.
ARCHIVES OF TOXICOLOGY (2008)
Human leukocyte antigens and drug hypersensitivity
Wen-Hung Chung et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Systematic reviews of adverse effects: framework for a structured approach
Yoon K. Loke et al.
BMC MEDICAL RESEARCH METHODOLOGY (2007)
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Shuen-Lu Hung et al.
PHARMACOGENETICS AND GENOMICS (2006)
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity
Ana Alfirevic et al.
PHARMACOGENOMICS (2006)
Clinical heterogeneity of drug hypersensitivity
JC Roujeau
TOXICOLOGY (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Genetic aspects of immune-mediated adverse drug effects
PJ Bugelski
NATURE REVIEWS DRUG DISCOVERY (2005)
Meta-analysis of genetic association studies
MR Munafò et al.
TRENDS IN GENETICS (2004)
Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay
YC Ou et al.
TOXICOLOGICAL SCIENCES (2003)
New allele frequency database: www.allelefrequencies.net
D Middleton et al.
TISSUE ANTIGENS (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Advances in immunology - The HLA system - First of two parts
J Klein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
